Core Insights - Adagene Inc. announced that its lead product ADG126 will be featured in two oral presentations at the CSCO Meeting in Jinan, China, from September 10-14, 2025 [1] Group 1: Clinical Developments - ADG126, a masked anti-CTLA-4 SAFEbody, is currently in Phase 1b/2 clinical studies in combination with pembrolizumab for treating advanced microsatellite-stable colorectal cancer (MSS CRC) [6][7] - The combination therapy has shown an objective response rate (ORR) of approximately 30% and over 80% disease control in refractory/resistant MSS CRC patients without liver metastasis, with a median overall survival (OS) of 19.4 months in the 10 mg/kg cohort [3] Group 2: Presentations at CSCO Meeting - Dr. Xu Ruihua will present updated results of the ADG126-P001 study on September 11, 2025, focusing on the efficacy of ADG126 combined with pembrolizumab in advanced MSS CRC [2] - Dr. Heinz-Josef Lenz will discuss the role of anti-CTLA-4 therapy in metastatic CRC, emphasizing the potential of ADG126 in treating cold tumors like MSS CRC [3] Group 3: Company Overview - Adagene Inc. is a clinical-stage biotechnology company focused on developing novel antibody-based cancer immunotherapies using its proprietary SAFEbody technology [4][5] - The company employs computational biology and artificial intelligence to design antibodies that meet unmet patient needs, and it has established strategic collaborations to enhance its research capabilities [4]

Nasdaq Copenhagen Nikolaj Plads 6DK-1067 Copenhagen K Copenhagen, 5 September 2025ANNOUNCEMENT no. 16/2025 Managers’ transactions Pursuant to Article 19 of the market abuse regulation Cemat A/S hereby announces the following information received 5 September 2025. Details of the person discharging managerial responsibilities/person closely associated Name:Jarosław LipińskiReason for the notification: Position/status:CEO in Cemat A/SInitial notification/Amendment:InitialDetails of the issuer, emission allo ...

Core Insights - iFLYTEK has launched its latest E-Ink tablet, AINOTE Air 2, in the European market through a partnership with Joybuy [1] - The Air 2 features German and Spanish system interfaces, enhancing its multilingual capabilities [2] - The tablet is designed for productivity, combining a lightweight design with advanced AI functions [3] Product Features - AINOTE Air 2 offers real-time voice-to-text transcription and AI-generated meeting summaries, improving efficiency in note-taking [4] - The tablet weighs only 230g and has a slim profile of 5–6.2mm, making it highly portable [6] - It includes a 2600mAh battery for all-day use and a 1440x1920 resolution screen to reduce eye strain [6] Target Audience - The Air 2 is tailored for professionals, students, and creatives, providing a bridge between traditional note-taking and modern AI-driven efficiency [7] Availability - AINOTE Air 2 is available in the UK and Germany starting September 5, 2025, through Joybuy [8]

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES OTTAWA, Ontario, Sept. 05, 2025 (GLOBE NEWSWIRE) -- (TSX: MNT/MNT.U) The Royal Canadian Mint (the “Mint”) announced today that it has completed its previously-announced follow-on offering of 833,200 exchange-traded receipts (“ETRs”) under the Mint’s Canadian Gold Reserves program at a price of C$53.18 per ETR for gross proceeds of C$44,309,576 (the “Offering”). The newly-issued ETRs have been listed on the Toronto Stock ...

Nasdaq Copenhagen Nikolaj Plads 6DK-1067 Copenhagen K Copenhagen, 5 September 2025ANNOUNCEMENT no. 15/2025 Closely related persons transactions Pursuant to Article 19 of the market abuse regulation Cemat A/S hereby announces the following information received 5 September 2025. Details of the person discharging managerial responsibilities/person closely associated Name:Peter Tærø NielsenReason for the notification: Position/status:Closely related person to Joanna Lucyna Iwanowska-Nielsen, member of the boar ...

Core Viewpoint - Nukkleus, Inc. has announced a private placement to raise approximately $10 million to fund strategic acquisitions and business expansion initiatives in the Aerospace and Defense sectors [1][2]. Funding Details - The private placement includes a $9.5 million investment from Esousa Group Holdings, LLC and a $500,000 investment from Sixth Borough Capital Fund, LP [1]. - The company will issue 200 units at a price of $50,000 each, consisting of Series A convertible preferred stock and common warrants [2]. Securities Information - Each Series A convertible preferred stock has a stated value of $50,000 and can be converted into 10,224 unregistered shares of common stock at a conversion price of $4.89 per share [2]. - Common warrants allow the purchase of one share of unregistered common stock at an exercise price of $5.405 per share [3]. Acquisition Plans - The net proceeds will be used for acquiring Tiltan Software Engineering Ltd., a defense market AI software provider, and 51% of Star 26 Capital, which owns RIMON, a supplier for the Iron Dome missile defense system [6]. - The company plans to establish advanced manufacturing zones in the Baltics and Israel through a joint venture with Mandragola Ltd. [6]. - Nukkleus aims to commercialize a drone payload license from Blade Ranger Ltd., marking its entry into commercial aviation services [6]. Closing and Regulatory Information - The closing of the private placement is expected around September 9, 2025, pending customary closing conditions [4]. - The securities are being offered in a private placement exempt from registration requirements under the Securities Act of 1933 [5]. Company Overview - Nukkleus focuses on acquiring and scaling suppliers in the defense, aerospace, and advanced manufacturing sectors, targeting Tier 2 and Tier 3 companies [9]. - The company aims to integrate operational capabilities and financial discipline to modernize and expand strategic suppliers, supporting dual-use innovation and resilient supply chains [10].

Core Insights - Imperial Petroleum Inc. reported a fleet expansion, increasing its number of vessels from 12 to 19 during Q2 2025, which is a significant milestone for the company [4][13] - The company experienced a decline in revenues and net income for Q2 2025 compared to Q2 2024, primarily due to decreased tanker market rates [4][31] - Despite the decline in revenues, the company remains profitable and debt-free, holding approximately $212 million in cash as of June 30, 2025 [13][11] Operational Highlights - Fleet operational utilization improved to 83.1% in Q2 2025 from 80.9% in Q2 2024 [4][22] - The fleet's book value increased by 54.4% to slightly above $350 million within a single quarter [4] - The average number of vessels owned increased from 10.3 in Q2 2024 to 14.1 in Q2 2025 [22] Financial Performance - Revenues for Q2 2025 were $36.3 million, a decrease of 22.8% from $47.0 million in Q2 2024 [4][31] - Net income for Q2 2025 was $12.8 million, down from $19.5 million in Q2 2024 [4][31] - For the first half of 2025, the company reported net income of $24.1 million and EBITDA of $31.8 million [4][11] Cash and Debt Position - Cash and cash equivalents, including time deposits, amounted to $212.2 million as of June 30, 2025, which is about 80% higher than the current market capitalization of approximately $120 million [4][11] - The company reported total debt of nil as of June 30, 2025 [11] Market Conditions - Average daily spot rates for product tankers decreased by $9,500, while Suezmax tankers saw an increase of about $1,000 compared to the same period last year [4] - Average daily one-year time charter rates for product and Suezmax tankers were about $12,000 and $18,000 lower, respectively, compared to Q2 2024 [4] Future Outlook - The CEO expressed optimism about the second half of 2025, anticipating favorable market rates for both tankers and drybulk carriers, which could lead to improved financial results [13]

Core Points - Lucid Diagnostics Inc. will host a conference call on September 8, 2025, at 8:30 AM ET to discuss the recent Contractor Advisory Committee meeting regarding the reconsideration of Local Coverage Determination for its EsoGuard® Esophageal DNA Test [1][2] - The EsoGuard® test is aimed at patients with GERD who are at risk of developing esophageal precancer and cancer, utilizing a noninvasive procedure for early detection [4] Company Overview - Lucid Diagnostics is a commercial-stage cancer prevention medical diagnostics company and a subsidiary of PAVmed Inc. [4] - The company focuses on early detection of esophageal precancer in at-risk patients through its EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device [4]

Core Insights - MAIA Biotechnology, Inc. announced the presentation of ateganosine (THIO) data at the 2025 IASLC World Conference on Lung Cancer, highlighting its potential in treating non-small cell lung cancer (NSCLC) [1][2] - The ongoing THIO-101 trial shows a median overall survival (OS) of 17.8 months, indicating substantial efficacy of ateganosine in late-stage NSCLC patients [3] - The FDA granted Fast Track designation for ateganosine, allowing for expedited regulatory processes and potential accelerated approval [4] Company Overview - MAIA Biotechnology is focused on developing targeted immunotherapies for cancer, with ateganosine as its lead program aimed at treating NSCLC patients with telomerase-positive cancer cells [10] - The company aims to improve and extend the lives of cancer patients through innovative therapies [10] Clinical Trial Details - The THIO-101 Phase 2 clinical trial is designed to evaluate the anti-tumor activity of ateganosine followed by PD-(L)1 inhibitors in advanced NSCLC patients who have shown resistance to previous treatments [9] - The trial has two primary objectives: assessing the safety and tolerability of ateganosine and evaluating its clinical efficacy using Overall Response Rate (ORR) as the primary endpoint [9] Conference Information - The IASLC World Conference on Lung Cancer serves as a platform for sharing cutting-edge research and fostering collaboration among industry leaders and experts [6] - MAIA's poster presentation is scheduled for September 7, 2025, focusing on metastatic non-small cell lung cancer and immunotherapy [8]

Core Viewpoint - Marimaca Copper Corp. has secured binding commitments for a brokered placement of 8,247,423 new Chess Depositary Interests (CDI) at a price of A$9.70 per CDI, resulting in gross proceeds of approximately A$80,000,000 or C$72,080,000 [1][2] Group 1 - The placement received strong support from new institutional and sophisticated investors, with demand significantly exceeding the targeted amount [2] - The net proceeds from the placement will be allocated for exploration at the Pampa Medina Project, detailed design and engineering at the Marimaca Oxide Deposit, and general corporate purposes [3] - The CDIs will be issued under an ASX Listing Rule 7.1 waiver, with completion expected around September 11, 2025, subject to regulatory approvals [4] Group 2 - Marimaca is focused on its 100%-owned Marimaca Copper Project and surrounding exploration properties located in the Antofagasta Region, Chile [7] - The Marimaca Copper Project includes the Marimaca Oxide Deposit, and the company is progressing through a Definitive Feasibility Study led by Ausenco Chile Ltda [8]